Russell Howerton, MD

home / authors / russell-howerton-md

Articles

Irinotecan/Gemcitabine Followed by Twice-Weekly Gemcitabine/Radiation in Locally Advanced Pancreatic Cancer

A. William Blackstock, Jr, MD;Susan A. Melin, MD;Jerome M. Butler, MD;Suzanne Patton, MD;Benjamin Pineau, MD;David Albertson, MD;Russell Howerton, MD;Edward Levine, MD

May 2nd 2002

Early clinical studies combining irinotecan (CPT-11, Camptosar) and gemcitabine (Gemzar) have yielded encouraging results. Gemcitabine administered via a twice-weekly schedule results in an enhanced radiation-sensitizing effect.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Published: April 21st 2021 | Updated: April 22nd 2025

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777